Guerbet

Guerbet

France - Villepinte
Biotechnology
WebsiteLinkedInCareers Page

Focus: Contrast Agents, Injectors

Guerbet is a life sciences company focused on Contrast Agents, Injectors.

OncologyNephrologyCardiovascularGastroenterologyNeurology
Funding Stage
PUBLIC
Open Jobs
0

Products & Portfolio (13)

13 discontinued products not shown

CONRAY
iothalamate meglumine
LOE Approaching
INJECTION · INJECTABLE
CLINICAL PHARMACOLOGY Following intravascular injection, Conray is rapidly transported through the circulatory system to the kidneys and is excreted unchanged in the urine by glomerular filtration. The pharmacokinetics of intravascularly administered radiopaque contrast media are usually best described by a two compartment model with a rapid alpha phase for drug distribution and a slower beta phase for drug elimination. In patients with normal renal function, the alpha and beta half-lives of Conray were approximately 10 and 90 minutes, respectively. Angiography may be performed following intravascular injection which will permit visualization until significant hemodilution occurs. Renal accumulation is sufficiently rapid that maximum radiographic density in the calyces and pelves occurs, in most instances, about 3 to 8 minutes after injection. In patients with impaired renal function, diagnostic opacification frequently is achieved only after prolonged periods. Injectable iodinated contrast agents are excreted either through the kidneys or through the liver. These two excretory pathways are not mutually exclusive, but the main route of excretion seems to be related to the affinity of the contrast medium for serum albumin. Iothalamate salts are poorly bound to serum albumin, and are excreted mainly through the kidneys. The liver and small intestine provide the major alternate route of excretion. In patients with severe renal impairment, the excretion of this contrast medium through the gallbladder and into the small intestine sharply increases. Iothalamate salts cross the placental barrier in humans and are excreted unchanged in human milk. The biliary system, pancreatic duct or joint spaces may be visualized by the direct injection of contrast medium into the region to be studied. CT Scanning of the Head When used for contrast enhancement in computed tomographic brain scanning, the degree of enhancement is directly related to the amount of iodine administered. Rapid injection of the entire dose yields peak blood iodine concentrations immediately following the injection, which fall rapidly over the next five to ten minutes. This can be accounted for by the dilution in the vascular and extracellular fluid compartments which causes an initial sharp fall in plasma concentration. Equilibration with the extracellular compartments is reached by about ten minutes; thereafter, the fall becomes exponential. Maximum contrast enhancement frequently occurs after peak blood iodine levels are reached. The delay in maximum contrast enhancement can range from five to forty minutes, depending on the peak iodine levels achieved and the cell type of the lesion. This lag suggests that the contrast enhancement of the image is at least in part dependent on the accumulation of iodine within the lesion and outside the blood pool. In brain scanning, the contrast medium (Conray) does not accumulate in normal brain tissue due to the presence of the "blood brain barrier." Th
1962
30
CYSTO-CONRAY
iothalamate meglumine
LOE Approaching
Intravesical, Ureteral · Solution
CLINICAL PHARMACOLOGY The most important characteristic of contrast media is the iodine content. The relatively high atomic weight of iodine contributes sufficient radiodensity for radiographic contrast. Following instillation by sterile catheter, Cysto-Conray II provides for visualization of the lower urinary tract. Clinical literature reports indicate that routinely less than 1 percent of a retrograde urographic radiopaque is absorbed systemically, however, as much as 12 percent absorption was observed with pyelorenal back flow and may produce iodine medicated thyrotropic effects described under .
1972
30
CYSTO-CONRAY II
iothalamate meglumine
LOE Approaching
INTRAVESICAL · SOLUTION
CLINICAL PHARMACOLOGY The most important characteristic of contrast media is the iodine content. The relatively high atomic weight of iodine contributes sufficient radiodensity for radiographic contrast. Following instillation by sterile catheter, Cysto-Conray II provides for visualization of the lower urinary tract. Clinical literature reports indicate that routinely less than 1 percent of a retrograde urographic radiopaque is absorbed systemically, however, as much as 12 percent absorption was observed with pyelorenal back flow and may produce iodine medicated thyrotropic effects described under .
1972
30
DOTAREM
gadoterate meglumine
Peak
INTRAVENOUS · SOLUTION
field. The magnetic moment enhances the relaxation rates of water protons in its vicinity, leading to an increase in signal intensity (brightness) of tissues. In magnetic resonance imaging (MRI), visualization of normal and pathological tissue depends in part on variations in the radiofrequency signal intensity that occurs with: differences in proton density differences of the spin-lattice or longitudinal relaxation times (T1) differences in the spin-spin or transverse relaxation time (T2) When placed in a magnetic field, gadoterate shortens the T1 and T2 relaxation times in target tissues. At recommended doses, the effect is observed with greatest sensitivity in the T1-weighted sequences.
2013
30
ELUCIREM
gadopiclenol
Peak
INTRAVENOUS · SOLUTION
(macrocyclic non-ionic complex of gadolinium) that develops a magnetic moment when placed in a magnetic field. The magnetic moment alters the relaxation rates of water protons in its vicinity in the body, leading to an increase in signal intensity (brightness) of tissues.
older for use with magnetic resonance imaging (MRI) to detectvisualize lesions with abnormal vascularity in: the central nervous system (brainspine+7 more
2022
0
LIPIODOL
ethiodized oil
LOE Approaching
INTRALYMPHATIC, INTRAUTERINE · OIL
X-Ray Contrast Activity
Radiographic Contrast Agent
1954
30
MD-GASTROVIEW
diatrizoate meglumine and diatrizoate sodium
Post-LOE
ORAL, RECTAL · SOLUTION
CLINICAL PHARMACOLOGY The most important characteristic of contrast media is the iodine content. The relatively high atomic weight of iodine contributes sufficient radiodensity for radiographic contrast with surrounding tissues. Diagnostic enteral radiopaque agents have few known pharmacological effects. Diatrizoate meglumine and diatrizoate sodium exert a mild laxative effect attributable to their high osmolarity. Diatrizoate meglumine and diatrizoate sodium are sparingly absorbed from the intact gastrointestinal tract, and therefore permit gastrointestinal opacification and delineation after oral or rectal administration. Oral administration is used for radiographic evaluation of the esophagus, stomach and proximal small intestine. Rectal administration is used for examination of the colon; however, visualization of the distal small bowel is generally unsatisfactory, since the hypertonicity of the medium causes intraluminal diffusion of water with subsequent dilution of the medium. Enough absorption from the gastrointestinal tract to permit incidental visualization of the urinary tract has been reported; this should also be considered when thyroid testing is being contemplated, since iodine-mediated thyrotropic effects may occur ( see ).
1981
30
OPTIRAY 300
ioversol
LOE Approaching
INJECTION · INJECTABLE
X-Ray Contrast Activity
1988
30
OPTIRAY 320
ioversol
LOE Approaching
INJECTION · INJECTABLE
X-Ray Contrast Activity
1988
30
OPTIRAY 320
ioversol
LOE Approaching
INJECTION · INJECTABLE
X-Ray Contrast Activity
1998
30
OPTIRAY 350
ioversol
LOE Approaching
INJECTION · INJECTABLE
X-Ray Contrast Activity
1988
30
OPTIRAY 350
ioversol
LOE Approaching
INJECTION · INJECTABLE
X-Ray Contrast Activity
1998
30
View all 13 products

Pipeline & Clinical Trials

Evaluation of Nephrogenic Systemic Fibrosis (NSF) in Patients With Chronic Kidney Disease Following
Nephrogenic Systemic Fibrosis
N/A
Clinical Trials (1)
NCT00811863Evaluation of Nephrogenic Systemic Fibrosis (NSF) in Patients With Chronic Kidney Disease Following OptiMARK Injection
N/A
Radiology
Liver Lesion
N/A
Clinical Trials (1)
NCT06596616Gadopiclenol vs Gadoxetate MRI for Liver Lesions
N/A
Predictive Value of FDG PET/CT, DWI and DCE-MRI Scans for Non-small Cell Lung Cancer Patients Receiv
Non-small Cell Lung Cancer
N/A
Clinical Trials (1)
NCT01482182Predictive Value of FDG PET/CT, DWI and DCE-MRI Scans for Non-small Cell Lung Cancer Patients Receiving Chemotherapy
N/A
MR mammography with Dotarem
MR Mammography With Dotarem
N/A
Clinical Trials (1)
NCT03041298Post Marketing Surveillance Study for Evaluation of Efficacy and Safety of Dotarem in Magnetic Resonance Mammography
N/A
Biannual ultrasonography
Hepatocellular Carcinoma
N/A
Clinical Trials (1)
NCT03731923Abbreviated MRI for HCC Surveillance
N/A
Observational Study on the Incidence of NSF in Renal Impaired Patients Following Dotarem Administrat
Renal Insufficiency
N/A
Clinical Trials (1)
NCT01467271Observational Study on the Incidence of NSF in Renal Impaired Patients Following Dotarem Administration
N/A
Observational Post-marketing Study on the Safety and Efficacy of Dotarem® (SECURE Study)
General Safety Profile of DOTAREM
N/A
Clinical Trials (1)
NCT01523873Observational Post-marketing Study on the Safety and Efficacy of Dotarem® (SECURE Study)
N/A
CE MRI on 0.064T Scanner
Image
N/A
Clinical Trials (1)
NCT06127810MRI Gadopiclenol Enhanced Imaging of CNS Tumors
N/A
Safety and Performance of Vectorio® in Conventional Trans-Arterial Chemo-Embolization (cTACE): A Pos
Oncology
N/A
Clinical Trials (1)
NCT05316077Safety and Performance of Vectorio® in Conventional Trans-Arterial Chemo-Embolization (cTACE): A Post-Market Clinical Follow-up
N/A
Standard of care Ultra Low Contrast PCI
Acute Kidney Injury
N/A
Clinical Trials (1)
NCT04928092A Zero Acute Kidney Injury Strategy for Percutaneous Coronary Intervention in Patients With ChronicKidney Disease
N/A
Gadolinium analysis in bone and tissue samples
Focus: Long-term Retention of Gadolinium-based Contrast Agent
N/A
Clinical Trials (1)
NCT01853163Long-Term Retention of Gadolinium in Bone
N/A
N/A
Clinical Trials (1)
NCT03910114Gadolinium-Based-Contrast-Agents (GBCA) Enhancement During MR Urography
N/A
Lipiodol® uterine treatment prior to IVF/ICSI
IVF
N/A
Clinical Trials (1)
NCT06563908Lipiodol Prior to FET (LIFE)
N/A
N/A
Clinical Trials (1)
NCT06703450Guerbet Liver Fibrosis
N/A
Pancreatic Duct Evaluation in Autoimmune Pancreatitis: MR Pancreatography
Pancreatitis, Chronic
N/A
Clinical Trials (1)
NCT01773031Pancreatic Duct Evaluation in Autoimmune Pancreatitis: MR Pancreatography
N/A
Unenhanced MRI
Multiple Sclerosis
N/A
Clinical Trials (1)
NCT02992847Evaluation of Potential Accumulation of Gadolinium (Dotarem and Multihance) in the French Observatory of Multiple Sclerosis (Www.Ofsep.Org/)
N/A
N/A
Clinical Trials (1)
NCT02173119Can Quantitative MRI After cTACE Help Predict Survival ?
N/A
Embozene Microspheres
Knee Pain Chronic
N/A
Clinical Trials (1)
NCT05248308Genicular Artery Embolization (GAE) for the Treatment of Chronic Post Knee Arthroplasty Pain
N/A
N/A
N/A
Clinical Trials (1)
NCT03023566Intra-individual Open-label, Single Center Study to Compare Unenhanced MRI With Dotarem Enhanced MRI
N/A
Gadavist 15Ml Solution for Injection
Myocardial Perfusion Imaging
N/A
Clinical Trials (1)
NCT03937921Dotarem Evaluation for Myocardial Perfusion CMR
N/A
CT examination
Patient Participation
N/A
Clinical Trials (1)
NCT05537779Safety and Performance of Optivantage Multi-use When Injecting Contrast Media for Contrast Enhanced CT Examination
N/A
N/A
Clinical Trials (1)
NCT03048006Post-marketing Surveillance Study for Evaluation of Dotarem Safety
N/A
Cardiac MRI taken using contrast agent, Dotarem®
Coronary Artery Disease
N/A
Clinical Trials (1)
NCT03057561Efficacy of Dotarem® (Gd-DOTA) Versus Gadovist® (Gd-DO3A-butrol) for Late Gadolinium Enhancement Cardiac Magnetic Resonance
N/A
Developing MRI Technologies for Atrial Fibrillation
Atrial Fibrillation (AF)
N/A
Clinical Trials (1)
NCT07083115Developing MRI Technologies for Atrial Fibrillation
N/A
gadopiclenol
Pharmacokinetics
Phase 1
Clinical Trials (1)
NCT04906005Pharmacokinetics and Safety of Gadopiclenol in Japanese Healthy Volunteers
Phase 1
Abbreviated MRI protocol: initial experience with Dotarem®
Breast Neoplasms
Phase 1
Clinical Trials (1)
NCT04341129Abbreviated MRI Protocol: Initial Experience With Dotarem® (Gadoterate Meglumine)
Phase 1
Dotarem® IV injection at 0.1 mmol/kg
End-stage Renal Failure
Phase 1
Clinical Trials (1)
NCT01449266Safety and Dialysability of Dotarem® in Dialysed Patients
Phase 1
Phase 1
Clinical Trials (1)
NCT04733092Safety and Efficacy of a Lipiodol Emulsion for the Embolization of Hypervascularizations in Patients With Knee Pain (LipioJoint1)
Phase 1
Phase 1
Clinical Trials (1)
NCT05490381Preoperative Embolization of Hypervascular Head and Neck Tumors to Improve Surgical Outcomes
Phase 1
P03277 0.1 mmol/kg
Healthy Volunteers
Phase 1
Clinical Trials (1)
NCT03657264Cardiac Safety Evaluation of P03277
Phase 1
Phase 1
Clinical Trials (1)
NCT03657784Pharmacokinetics, Dialysability and Safety of P03277 in Healthy Volunteers and in Patients With Impaired Renal Function
Phase 1
Phase 1/2
Clinical Trials (1)
NCT03603106Pharmacokinetics, Pharmacodynamics Profile and Tolerance of P03277 in Healthy Subjects and Patients With Brain Lesions
Phase 1/2
Phase 2
Clinical Trials (1)
NCT06114082TACE Using Idarubicin Versus Doxorubicin Chemoemulsion in Patients with Hepatocellular Carcinoma
Phase 2
Idarubicin and Lipiodol
Carcinoma, Hepatocellular
Phase 2
Clinical Trials (1)
NCT03727633Hepatocellular Carcinoma on Cirrhosis With Child A/B7 and Hepatic Intra Arterial Injection of Idarubicin/Lipiodol Emulsion
Phase 2
Lipiodol
Liver Cancer
Phase 2
Clinical Trials (1)
NCT01877187Lipiodol as an Imaging Biomarker in Patients With Primary and Metastatic Liver Cancer
Phase 2
Phase 2
Clinical Trials (1)
NCT03749252Pharmacokinetics, Safety and Efficacy of P03277 in Pediatric Patients Undergoing Central Nervous System Contrast-enhanced MRI
Phase 2
Phase 2
Clinical Trials (1)
NCT02724540Randomized Embolization Trial for NeuroEndocrine Tumor Metastases to the Liver
Phase 2
Phase 2
Clinical Trials (1)
NCT05590884Gadopiclenol Pharmacokinetics, Safety and Efficacy in Children < 2 Years of Age
Phase 2
P03277 at 0.1 mmol/kg
Chronic Liver Disease
Phase 2
Clinical Trials (1)
NCT02973516Proof of Concept Study Concerning Efficacy of P03277 MR Imaging in HCC Diagnosis
Phase 2
Phase 2
Clinical Trials (1)
NCT02633501P03277 Dose Finding Study in Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)
Phase 2
Phase 3
Clinical Trials (1)
NCT07348640Evaluation of the Efficacy and Safety of Magnetic Resonance Angiography (MRA) Using Gadopiclenol Compared to Gadoterate Meglumine in the Assessment of Steno-occlusive Disease in Adult Patients With Suspected Vascular Disease
Phase 3
Phase 3
Clinical Trials (1)
NCT01010932Carotid and Vertebral Magnetic Resonance Angiography (MRA) Study Comparing Dotarem and Time Of Flight (TOF)
Phase 3
Phase 3
Clinical Trials (1)
NCT01211873Safety and Efficacy Evaluation of DOTAREM® in MRI of Central Nervous System (CNS) Lesions
Phase 3
Phase 3
Clinical Trials (1)
NCT01012674Carotid and Vertebral Magnetic Resonance Angiography (MRA) Study Comparing Dotarem and Time Of Flight (TOF)
Phase 3
gadopiclenol
CNS Lesion
Phase 3
Clinical Trials (1)
NCT03996447Efficacy and Safety of Gadopiclenol for Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)
Phase 3
Phase 3
Clinical Trials (1)
NCT03986138Efficacy and Safety of Gadopiclenol for Body Magnetic Resonance Imaging (MRI)
Phase 3
Phase 3
Clinical Trials (1)
NCT00980681Renal Magnetic Resonance Angiography (MRA) Study Comparing Dotarem and Time-Of-Flight (TOF)
Phase 3
Phase 3
Clinical Trials (1)
NCT06057168Performance of Elucirem in DSC-MRI Perfusion of Brain Gliomas
Phase 3
Phase 3
Clinical Trials (1)
NCT06010173Evaluation of Gadopiclenol for Magnetic Resonance Imaging (MRI) in Japanese Adults and Children
Phase 3

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts
Portfolio: 26 approved products, 74 clinical trials
Top TAs: Oncology, Nephrology, Cardiovascular
Publications: 25 in PubMed
Portfolio Health
Peak2 (8%)
LOE Approaching23 (88%)
Post-LOE1 (4%)
26 total products
Therapeutic Area Focus
Oncology
16 pipeline
Nephrology
10 pipeline
Cardiovascular
6 pipeline
Immunology
1 pipeline
Neurology
1 pipeline
Marketed
Pipeline